• 1
    Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981; 305: 139-53.
  • 2
    Casazza AM. Antitumor activity of anthracyclines: experimental studies. In: MuggiaFM, YoungCW, editors. Anthracycline antibiotics in cancer therapy. Boston: Martinus Nijhoff, 1982: 13-29.
  • 3
    Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992; 19: 529-42.
  • 4
    Minow RA, Benjamin RS, Gottlieb JA. Adriamycin (NSC-123127) cardiomyopathy: an overview with determination of risk factors. Cancer Chemother Rep 1975: 6; 195-201.
  • 5
    Bristow MR, Lopez MB, Mason JW. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 1982; 50: 32-41.
  • 6
    Torti FM, Bristow MR, Howes AE. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy. Ann Intern Med 1983; 99: 745-9.
  • 7
    Legha SS, Benjamin RS, Mackay B. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133-9.
  • 8
    Speyer JL, Green MD, Ward C. A trial of ICRF-187 to selectively protect against chronic adriamycin toxicity: rationale and preliminary results of a clinical trial. In: HackerMP, LazoJS, TrittonTR, editors. Organ directed toxicities of anticancer drugs. Boston: Martinus Nijhoff, 1988: 17-30.
  • 9
    Weiss RB, Clagett C, Russo M, et al. Anthracycline analogs: the past, present and future. Cancer Chemother Pharmacol 1985; 3: 818-26.
  • 10
    Jain KK, Casper ES, Geller NL. A prospective randomised comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985; 3: 818-26.
  • 11
    Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of advanced diffuse large cell lymphoma. Ann Intern Med 1985; 102: 596-602.
  • 12
    Dresdale A, Bonow RO, Wesley R, et al. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 1983; 52: 51-60.
  • 13
    Casazza AM. Experimental evaluation of anthracycline analogs. Cancer Treat Rep 1979; 63: 835-44.
  • 14
    Bristow M. Rational system for cardiac monitoring in patients receiving anthracyclines [abstract]. Proc Am Soc Clin Oncol 1980; 21: 356.
  • 15
    Gottdiener JS, Mathisen DJ, Borer JS, et al. Doxorubicin cardiotoxicity: assessment of late ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 1981; 94: 430-5.
  • 16
    Brambilla C, Rossi A, Bonfante L, et al. Phase II study comparing doxorubicin (Dx) versus 4'-epidoxorubicin (Epi-Dx) in metastatic breast cancer.Communication to the Second European Conference on Clinical Oncology, Amsterdam, the Netherlands, November 2-5 1983.
  • 17
    Armand JP, Hurteloup P, Hayat M, et al. Phase III chemotherapy comparing FAC versus FEC in advanced breast cancer: preliminary results [abstract]. Proc Am Soc Clin Oncol 1984; 3: 118.
  • 18
    Saad AD, Al-Ismail, Whittaker JA, Gough J. Combination chemotherapy including epirubicin for the management of non Hodgkin's lymphoma. Eur J Cancer Oncol 1987; 1379-84.
  • 19
    Lena De M, Marzullo F, Colucci G, Lorusso V, Brandi M. Randomized trial with two CHOP-B regimens (with doxorubicin or epirubicin) in poor prognosis non-Hodgkin's lymphomas. Clin Trials J 1987; 24: 223-9.
  • 20
    Schneider AM, Straus DJ, Schluger AE, et al. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate and high grade non-Hodgkin's lymphomas. J Clin Oncol 1990; 8: 94-102.
  • 21
    Southwest Oncology Group study Weick JK, Dahlberg S, Fisher RI. Combination chemotherapy of intermediate and high grade non Hodgkin's lymphoma with MACOP-B:. J Clin Oncol 1991; 9: 748-53.
  • 22
    Vitolo U, Bertni M, Brusamolini E, et al. MACOP-B treatment in diffuse large cell lymphomas: identification of prognostic groups in an Italian multicenter study. J Clin Oncol 1992; 10: 219-27.
  • 23
    Gopal R, Nair R, Saikia TK, et al. Modified MACOP-B chemotherapy for intermediate and high grade non-Hodgkin's lymphomas. JAPI 1994; 42: 781-4.
  • 24
    Barrios CH, Weiss PD. MACOP-B for the treatment of large cell lymphoma: preliminary results at Washington University [Abstract 242a]. Blood 1987; 70: 824.
  • 25
    Froimmtchuck M, Olivatto LO, Gil RA. MACOP-B effective treatment for diffuse unfavourable non-Hodgkin's lymphomas (NHL) [Abstract C-936]. Proc Am Soc Clin Oncol 1988; 7: 242.
  • 26
    Oster W, Hermann F, Lindemann A. Treatment of high and intermediate grade non-Hodgkin's lymphoma (NHL) with MACOP-B chemotherapy [Abstract C-937]. Proc Am Soc Clin Oncol 1988; 7: 242.
  • 27
    Reyroso EE, Sobrevilla PJ, Lara FU, et al. MACOP-B for advanced intermediate and high grade non-Hodgkin's lymphoma (NHL) with poor prognostic features: preliminary experience of the Institute Nacional de Cancerolgta Mexico[Abstract C-920]. Proc Am Soc Clin Oncol 1988; 7:239.
  • 28
    Gianni AM, Brgni M, Siena S, Brambilla C, et al. High-dose chemotherapy and autologous bone marrow transplant compared with MACOP-B in aggressive B-cell lymphoma 1997;336:1290-7.